Study of Diversity of Metformin Related Gastrointestinal Side Effects
Abstract
INTRODUCTION: Digestive disorders represent the most common metformin related side-effects in type 2 diabetics. GI side effects of metformin are not so uncommon rather under reported or wrongly diagnosed as primary gastrointestinal disorder. This study is to estimate metformin related GI side effects in Indian population.
METHODOLOGY: This is a retrospective cross sectional study, conducted in tertiary care hospital at Kota. 120 type 2 diabetic patients were included after detailed history, physical examination and inclusion/exclusion criteria, who were on metformin tablet only, for variable duration. All patients were evaluated for gastrointestinal side effects.
RESULTS: Mean age of study group was 52.8±11.9 years with mean weight 72.4±10.3 kg. Mean duration of metformin therapy was 3 years (6 weeks to 6 years) and mean metformin dose was 1000mg (500 mg - 2500 mg). 62 (51.66%) patients presented with GI side effects. These side effects are diarrhea (33), nausea/vomiting (28), pain abdomen (23), flatulence (16), retching (13), dysgeusia (7). On the basis of duration of therapy, most of patients had side effects during initial phase of treatment but some patients also presented after long duration of treatment.
CONCLUSION: Gastrointestinal side effects being most common side effect of metformin can lead to discontinuation of therapy. So before extensive evaluation of any GI problem in patient on metformin, other methods can be tried like temporary discontinuation, dose…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.